# Vanda Pharmaceuticals Inc. (VNDA) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $5.43, market value $328 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Vanda Pharmaceuticals Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 1.5×**. Each dollar of revenue is priced at 1.5×.
- **Price / book: 1.2×**. The shares trade at 1.2× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -43.6%** (5-yr avg -1.5%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -86.1%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -102.0%**. The company reported a net loss over the last twelve months.
- **Return on equity: -67.4%**. Return on equity is negative because earnings are negative.
- **Return on assets: -56.2%**. Each dollar of assets produces -56.2% of profit.

## Growth
- **Revenue growth (1 yr): 8.7%** (3-yr -5.3%/yr, 5-yr -2.7%/yr). Revenue grew 8.7% over the last year, against -2.7% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): -1033.3%**. Earnings per share fell 1033.3%, slower than revenue, so margins compressed.

## Financial health
- **Current ratio: 2.39** (quick 2.39). Current assets cover the next year's liabilities 2.39 times.
- **Altman Z-score: 2.07**. A Z-score of 2.07 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Vanda Pharmaceuticals Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 17.0%** (YTD -38.4%, 3-mo -10.0%). The shares are up 17.0% over twelve months including dividends.
- **From 52-week high: -45.4%** (27.2% above the low). Trading 45% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 52**. An RSI of 52 is neutral.
- **Beta (1 yr): 0.80** (volatility 82%). Beta of 0.80 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=VNDA · Page: https://foliofundamentals.com/stocks/vnda

Not investment advice.